Ipamorelin: Switching From or To Other Drugs in Its Class

What Ipamorelin Is and How It Works

Ipamorelin is a synthetic pentapeptide that binds the growth-hormone secretagogue receptor type 1a (GHS-R1a), the same receptor activated by the endogenous hunger hormone ghrelin, and triggers pulsatile GH release from the anterior pituitary. Unlike earlier GHRPs, it produces this effect without clinically significant rises in cortisol, prolactin, or ACTH at standard doses [1].

Receptor Pharmacology

The GHS-R1a receptor is expressed on somatotroph cells in the anterior pituitary and on hypothalamic neurons that release growth-hormone-releasing hormone (GHRH). When ipamorelin occupies GHS-R1a, it triggers a G-protein-coupled signaling cascade that raises intracellular calcium and stimulates GH secretion [2]. This mechanism is distinct from GHRH-receptor agonists such as sermorelin and CJC-1295, which act at the GHRH receptor rather than GHS-R1a.

Selectivity Compared to Earlier GHRPs

Raun et al. (Eur J Endocrinol, 1998, PMID 9678526) tested ipamorelin in rats and pigs alongside GHRP-6, GHRP-2, and growth hormone-releasing peptide-1. Ipamorelin produced GH peaks equivalent to GHRP-6 and GHRP-2 at equimolar doses, yet cortisol and prolactin levels were not significantly elevated above baseline, a selectivity profile not seen with either comparator [1]. The authors concluded that ipamorelin "represents a new class of GH secretagogues with a unique selectivity for GH release." This selectivity is the primary pharmacological reason clinicians choose ipamorelin as a default starting GHRP before considering more potent alternatives.

Half-Life and Dosing Pulse Timing

Ipamorelin has a plasma half-life of roughly 2 hours in animal models [1]. GH peaks occur approximately 15-30 minutes after subcutaneous injection. Because GH pulsatility matters for downstream IGF-1 synthesis, dosing is timed to mimic physiological nocturnal GH surges: a common protocol is one injection 30-60 minutes before sleep, with optional morning and midday doses for patients targeting body composition changes [3].

The Drug Class: GH Secretagogues and Where Ipamorelin Fits

Growth-hormone secretagogues fall into two mechanistically distinct groups. Understanding this split is the foundation of any rational switching decision.

Group 1: GHS-R1a Agonists (GHRPs and Ghrelin Mimetics)

This group includes ipamorelin, GHRP-2, GHRP-6, hexarelin, and MK-677 (ibutamoren). All bind GHS-R1a. They differ primarily in receptor affinity, off-target receptor activity, and resulting side-effect profiles.

• GHRP-6 stimulates appetite robustly by cross-activating motilin receptors in the gut, producing noticeable hunger within 30 minutes of injection [4].
• GHRP-2 raises cortisol and prolactin more than ipamorelin does at comparable GH-stimulating doses [5].
• Hexarelin is the most potent GHS-R1a agonist in this series but also binds CD36 scavenger receptors and has cardiac activity that is not well characterized in long-term human trials [6].
• MK-677 is an orally active, non-peptide GHS-R1a agonist with a half-life exceeding 24 hours, making it pharmacologically the farthest from ipamorelin within the same receptor class [7].

Group 2: GHRH-Receptor Agonists

Sermorelin, CJC-1295 (with or without drug-affinity complex, DAC), mod-GRF(1-29), and tesamorelin all bind the GHRH receptor rather than GHS-R1a. Their mechanism is additive, not redundant, when combined with a GHRP. Tesamorelin (Egrifta) is the only FDA-approved compound in either group, indicated specifically for HIV-associated lipodystrophy [8].

Why the Distinction Matters for Switching

A patient switching from ipamorelin to sermorelin is switching receptor classes entirely. There is no pharmacodynamic competition between the two at the receptor level, so no formal washout is needed for efficacy reasons. Switching within the GHRP class (for example, ipamorelin to GHRP-2) does involve the same receptor, and residual occupancy from the prior compound could theoretically blunt the initial response to the new agent during the first 24-48 hours [9].

Switching From Ipamorelin to GHRP-2 or GHRP-6

Patients and clinicians sometimes move to GHRP-2 or GHRP-6 when ipamorelin produces insufficient IGF-1 elevation or inadequate body composition response after 8-12 weeks at standard doses (200-300 mcg three times daily).

Dose Equivalence

No head-to-head human RCT has established formal dose conversion ratios between these peptides. Based on the dose-response data in Raun et al. [1] and receptor-binding affinity data published by Holst and Schwartz (2004), a practical approach is to start GHRP-2 or GHRP-6 at the same microgram dose as the final ipamorelin dose, then titrate upward by 50 mcg per injection based on IGF-1 response and side effects [10].

Washout Recommendation

Allow 24-48 hours between the last ipamorelin dose and the first GHRP-2 or GHRP-6 dose. GHS-R1a receptor internalization following repeated GHRP exposure typically recovers within this window [9]. Longer washout (72 hours) may be prudent if the patient was dosing three times daily for more than 12 weeks, as chronic high-frequency stimulation may downregulate receptor expression.

Side Effects to Anticipate After Switching

Switching to GHRP-6 will almost certainly increase appetite significantly. In Petersenn et al. (1998), GHRP-6 produced a 36% increase in caloric intake over a controlled test meal compared to placebo [4]. Patients who chose ipamorelin specifically to avoid hunger should be counseled on this before transitioning. GHRP-2 carries less hunger effect than GHRP-6 but produces measurable cortisol elevation (roughly 30-60% above baseline at 1 mcg/kg IV) [5]. This matters for patients with adrenal sensitivities or anxiety disorders.

Switching From Ipamorelin to Sermorelin or CJC-1295

Moving from ipamorelin to a GHRH-class compound shifts the mechanism from GHS-R1a to the GHRH receptor. This is a true receptor-class switch.

No Pharmacodynamic Washout Required

Because the two receptor types do not compete, a patient can begin sermorelin the morning after the last ipamorelin injection with no efficacy concern from residual receptor occupancy. A brief gap of 12-24 hours is reasonable for patient simplicity and clinical record-keeping, but no physiological requirement for longer washout exists [9].

CJC-1295 Without DAC vs. CJC-1295 With DAC

Mod-GRF(1-29) (CJC-1295 without DAC) has a half-life of 30 minutes and is typically injected alongside ipamorelin as a stack, the two peptides synergize because they act on different receptors simultaneously [11]. CJC-1295 with DAC binds albumin via a reactive lysine and has a half-life of 6-8 days, producing near-continuous GHRH-receptor stimulation. When switching a patient from ipamorelin monotherapy to the CJC-1295 DAC plus ipamorelin combination, no washout of ipamorelin is needed; the two agents are additive.

Sermorelin Dosing After Ipamorelin

Sermorelin is typically dosed at 100-300 mcg per injection subcutaneously, once daily at bedtime [3]. When converting from ipamorelin, start at 200 mcg sermorelin nightly. Recheck IGF-1 at 6-8 weeks. IGF-1 responses to sermorelin are generally smaller in magnitude than to GHRP-based regimens in patients over 45, as somatotroph responsiveness to GHRH declines with age more than GHS-R1a responsiveness does [12].

Switching From Ipamorelin to Tesamorelin

Tesamorelin (Egrifta SV, Theratx) is the only FDA-approved GH secretagogue. Its labeled indication is reduction of excess abdominal fat in HIV-positive adults with lipodystrophy, at a dose of 2 mg subcutaneously once daily [8]. Outside that indication, it is used off-label in similar fashion to other GHRH agonists.

Regulatory and Pharmacological Context

Because tesamorelin is FDA-approved, a switch from compounded ipamorelin to tesamorelin requires a standard prescription and insurance authorization where applicable. Tesamorelin is a GHRH analogue with a trans-3-hexenoic acid modification that slows dipeptidyl peptidase-IV (DPP-IV) degradation, extending its active half-life to approximately 26 minutes compared to sermorelin's 10-12 minutes [13]. In the LIPO-010 trial (N=412), tesamorelin 2 mg daily reduced visceral adipose tissue by 18% over 26 weeks vs. 2% placebo (P<0.001) [14].

Washout Before Starting Tesamorelin

A 3-to-7-day washout from ipamorelin is clinically reasonable before starting tesamorelin, not because of receptor competition (they act on different receptors) but to establish a clean IGF-1 baseline for monitoring. FDA prescribing information for Egrifta SV notes that IGF-1 should be measured at baseline and monitored every 6 months during therapy [8].

Dose and Monitoring After Switch

Start tesamorelin at 2 mg subcutaneously every morning. Check IGF-1 and fasting glucose at 8 weeks. Tesamorelin raises IGF-1 more reliably than ipamorelin in the lipodystrophy population because GHRH-receptor responsiveness is preserved in that context. One concern: tesamorelin may impair glucose tolerance. In LIPO-010, fasting glucose rose by 4 mg/dL and HbA1c by 0.12% in the tesamorelin group [14]. Screen patients with pre-diabetes carefully before this switch.

Switching From GHRP-2, GHRP-6, or Hexarelin to Ipamorelin

Clinicians frequently move patients to ipamorelin from a more potent GHRP after side effects, appetite dysregulation, water retention, cortisol elevation, or gynecomastia risk (via prolactin).

Tapering vs. Abrupt Switch

No evidence supports a taper when discontinuing GHRPs. Because exogenous GH-secretagogue peptides do not suppress endogenous GH production the way exogenous GH does, there is no HPA-axis suppression or rebound to manage [1]. Abrupt discontinuation is acceptable. Allow 24-48 hours before starting ipamorelin to reduce receptor desensitization carry-over [9].

Starting Dose for Ipamorelin After Higher-Potency GHRPs

Begin ipamorelin at 200 mcg per injection, the same starting dose used in treatment-naive patients. Do not increase to 300 mcg immediately, even if the patient was on high-dose hexarelin or GHRP-2, because the side-effect profile differs. Ipamorelin's ceiling effect on cortisol and prolactin holds even at doses above 500 mcg in animal models [1], so the risk of overshoot in those domains is low, but GH pulse amplitude should still be titrated based on IGF-1 at 6-8 weeks.

The HealthRX GHRP Switching Framework

Below is a structured decision tool used by the HealthRX clinical team when transitioning patients between GH secretagogues. It synthesizes receptor pharmacology, half-life data, and observed side-effect profiles.

Step 1. Identify the reason for switching. Appetite or cortisol side effects from current GHRP? Move to ipamorelin. Insufficient IGF-1 response to ipamorelin? Move to GHRP-2 or add CJC-1295.

Step 2. Determine receptor class of current and target agent. Same class (GHRP to GHRP): 24-48-hour washout. Different class (GHRP to GHRH agonist): 12-24-hour washout is sufficient, or no washout needed.

Step 3. Confirm IGF-1 baseline before the switch. Draw serum IGF-1 (LC/MS preferred) on the last day of the current protocol or within 72 hours of stopping it. This anchors the response comparison.

Step 4. Start new agent at standard starting dose regardless of prior dose. Receptor affinity and intrinsic efficacy differ between compounds. Prior dose is not a reliable conversion guide.

Step 5. Recheck IGF-1 at 6-8 weeks and adjust dose. The therapeutic IGF-1 target for most adults is the upper quartile of the age-adjusted reference range, roughly 200-350 ng/mL for patients aged 30-60 [12].

Step 6. Monitor side-effect-specific labs at the same 6-8-week check. For tesamorelin or GHRP-2: fasting glucose and cortisol-AM. For GHRP-6: body weight and appetite diary. For all: blood pressure (GH increases sodium retention at supratherapeutic IGF-1 levels) [15].

MK-677 (Ibutamoren): A Special Case in Switching

MK-677 is an orally bioavailable, non-peptide GHS-R1a agonist with a half-life of 24 hours and a half-life range of 4-6 days to full receptor-occupancy washout at steady state [7]. Switching from MK-677 to ipamorelin is the most pharmacologically complex GHRP transition because of MK-677's long tissue half-life.

Washout Before Starting Ipamorelin

Allow a minimum of 7 days after the last MK-677 dose before beginning ipamorelin. Ongoing GHS-R1a occupancy from residual MK-677 will blunt ipamorelin's acute GH pulses and make it impossible to evaluate the new agent's efficacy during the washout window [7].

Why Patients Make This Switch

MK-677 produces consistent IGF-1 elevation but also raises fasting glucose, prolactin, and causes significant water retention in many patients. In a 2-year randomized trial by Murphy et al. (J Clin Endocrinol Metab, 1998, N=65), MK-677 25 mg daily increased IGF-1 by 39% but also increased fasting blood glucose by 0.3 mmol/L and raised insulin levels significantly [7]. Ipamorelin's short half-life and pulsatile-only GH stimulation avoid the tonic IGF-1 elevation pattern that drives MK-677's glucose and insulin effects.

Combination Protocols: Ipamorelin Plus a GHRH Agonist

Co-administration of ipamorelin with mod-GRF(1-29) or CJC-1295 without DAC is one of the most commonly prescribed GHRP stacks. The rationale is receptor-level combination: GHRH-receptor stimulation amplifies the somatotroph's response to GHS-R1a stimulation by an additive or possibly multiplicative factor [11].

Evidence for Additive GH Release

Khorram et al. (J Clin Endocrinol Metab, 1997) demonstrated that simultaneous administration of a GHRP and GHRH in older adults produced GH pulses 2-to-3-fold larger than either agent alone at the same doses [16]. While that study used GHRP-2 rather than ipamorelin, the receptor mechanism is conserved across the GHRP class.

Transitioning a Patient From Monotherapy to the Stack

A patient stable on ipamorelin 200 mcg three times daily can add mod-GRF(1-29) at 100 mcg per injection without any washout or dose reduction of ipamorelin. The GHRH analogue is simply co-injected in the same syringe (they are physically compatible in the same diluent) or in a separate injection at the same time point. IGF-1 will typically rise by an additional 20-40% above the ipamorelin-only baseline within 4-6 weeks [16].

Safety Considerations Across All Switches

IGF-1 Ceiling and Acromegaly Risk

No peptide secretagogue has produced acromegalic features in human trials at standard doses, because the intact feedback loop (somatostatin release when GH rises) limits the maximal pulse amplitude. Ipamorelin does not override somatostatin feedback [1]. Still, IGF-1 should be kept below 1.3 times the upper limit of the age-adjusted reference range. The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults specifies that IGF-1 above the age-adjusted reference range warrants dose reduction before any additional titration [17].

Injection-Site Reactions

All subcutaneous GH secretagogues may cause transient erythema, induration, or lipohypertrophy at injection sites. Rotating injection sites (abdomen, thigh, upper arm) on each dose reduces this risk [3].

Drug Interactions

No formally characterized pharmacokinetic drug interactions exist for ipamorelin in the published literature. Glucocorticoids blunt GH pulsatility by increasing somatostatin tone; patients on chronic corticosteroids may show reduced IGF-1 responses to any GH secretagogue [17]. Insulin sensitizers (metformin, GLP-1 receptor agonists) do not appear to alter GHRP pharmacodynamics in published clinical data.